Yep with a current MC of 75m and all that is to come in next 6 months or so, adding to holdings sub 9c should be well rewarded.
This and DXB appear to be best placed BIOs with MC below 100m.
For me the priority review voucher here is a massive tick (if granted), whilst DXB have an orphan drug designation from FDA.
Not many bios can boast such credibilities and you only need to look at NEUs historical rise to a 2.5b or TLX to 4b to see potential here.
GLTAH
per-chart, page-128
-
- There are more pages in this discussion • 1,075 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
